Sensus Healthcare, Inc. (NASDAQ:SRTS) Stake Raised by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 8.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,404 shares of the company’s stock after acquiring an additional 11,525 shares during the quarter. Geode Capital Management LLC’s holdings in Sensus Healthcare were worth $849,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in SRTS. Acadian Asset Management LLC lifted its position in Sensus Healthcare by 578.6% in the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after buying an additional 38,474 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Renaissance Technologies LLC grew its stake in Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after purchasing an additional 100,294 shares in the last quarter. XTX Topco Ltd acquired a new position in Sensus Healthcare in the 2nd quarter worth about $95,000. Finally, Marshall Wace LLP raised its stake in shares of Sensus Healthcare by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after purchasing an additional 46,732 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SRTS has been the subject of several recent research reports. HC Wainwright increased their price target on shares of Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Maxim Group lifted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Stock Down 4.2 %

SRTS opened at $6.54 on Friday. The stock’s 50 day moving average price is $7.68 and its two-hundred day moving average price is $6.67. The firm has a market capitalization of $107.18 million, a P/E ratio of 11.47 and a beta of 1.21. Sensus Healthcare, Inc. has a 12-month low of $2.61 and a 12-month high of $9.33.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.